HUP0301405A2 - Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények - Google Patents

Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények

Info

Publication number
HUP0301405A2
HUP0301405A2 HU0301405A HUP0301405A HUP0301405A2 HU P0301405 A2 HUP0301405 A2 HU P0301405A2 HU 0301405 A HU0301405 A HU 0301405A HU P0301405 A HUP0301405 A HU P0301405A HU P0301405 A2 HUP0301405 A2 HU P0301405A2
Authority
HU
Hungary
Prior art keywords
component
preparation
solubility
compositions containing
active components
Prior art date
Application number
HU0301405A
Other languages
English (en)
Inventor
Edward D.S. Kerslake
Orest Olejnik
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22814167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0301405(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of HUP0301405A2 publication Critical patent/HUP0301405A2/hu
Publication of HUP0301405A3 publication Critical patent/HUP0301405A3/hu
Publication of HU230383B1 publication Critical patent/HU230383B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A találmány szerinti készítmények a következő komponensekettartalmazzák: - gyógyhatású komponens a készítménnyel kezelendőbetegen a kívánt terápiás hatás elérésére alkalmas mennyiségben, -ciklodextrintől eltérő oldékonyságfokozó komponens a készítménybenlévő gyógyhatású anyag oldékonyságának az oldékonyságfokozó komponenstnem tartalmazó, egyébként hasonló összetételű készítménybenészlelhetőhöz képesti megnövelésére alkalmas menynyiségben, - oxi-klórkomponens a készítmény tartósítását legalább elősegítő mennyiségben,és - folyékony hordozó komponens. Ó
HU0301405A 2000-07-14 2001-07-09 Oldékonyságfokozó komponens használata brimodinin-tartarátot tartalmazó vizes készítményekben HU230383B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21820600P 2000-07-14 2000-07-14
US60/218,206 2000-07-14
PCT/US2001/021551 WO2002005822A2 (en) 2000-07-14 2001-07-09 Compositions containing therapeutically active components having enhanced solubility

Publications (3)

Publication Number Publication Date
HUP0301405A2 true HUP0301405A2 (hu) 2003-08-28
HUP0301405A3 HUP0301405A3 (en) 2006-02-28
HU230383B1 HU230383B1 (hu) 2016-03-29

Family

ID=22814167

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301405A HU230383B1 (hu) 2000-07-14 2001-07-09 Oldékonyságfokozó komponens használata brimodinin-tartarátot tartalmazó vizes készítményekben

Country Status (23)

Country Link
US (2) US6562873B2 (hu)
EP (2) EP2153819B1 (hu)
JP (1) JP2004503593A (hu)
KR (1) KR20030023700A (hu)
CN (1) CN1441679A (hu)
AR (1) AR035039A1 (hu)
AU (2) AU7326801A (hu)
BR (1) BR0112461A (hu)
CA (1) CA2416169C (hu)
CY (1) CY1113391T1 (hu)
DK (1) DK2153819T3 (hu)
ES (1) ES2392636T3 (hu)
HU (1) HU230383B1 (hu)
IL (2) IL153322A0 (hu)
MX (1) MXPA02012206A (hu)
NO (1) NO331816B1 (hu)
NZ (1) NZ522610A (hu)
PL (1) PL361027A1 (hu)
PT (1) PT2153819E (hu)
RU (1) RU2291685C2 (hu)
TW (1) TWI287992B (hu)
WO (1) WO2002005822A2 (hu)
ZA (1) ZA200209877B (hu)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02008930A (es) * 2000-07-14 2003-03-31 Allergan Inc Composiciones que contienen componentes agonistas alfa-2-adrenergicos.
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
DK2153819T3 (da) * 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
US20050282774A1 (en) * 2000-10-31 2005-12-22 Eek Bjorn C Method and pharmaceutical to treat spinal discs
US20030114460A1 (en) * 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US6982079B2 (en) 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
AU2003261304A1 (en) * 2002-07-30 2004-02-16 Omeros Corporation Ophthalmologic irrigation solutions and method
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7022740B2 (en) * 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
EP2279005A1 (en) * 2008-05-19 2011-02-02 Alcon Research, Ltd. Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
WO2010014552A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
CA2750242C (en) 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP2555751B8 (en) 2010-04-03 2018-02-14 Praful Doshi Methods of coating a contact lens
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
EP2555750A2 (en) * 2010-04-07 2013-02-13 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
EP2621281A1 (de) 2010-10-01 2013-08-07 Elektra Management s.r.o. Lösung von guanidinium-verbindungen, verfahren unter einsatz dieser lösung sowie deren verwendung
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
KR102017922B1 (ko) 2011-12-07 2019-09-03 알러간, 인코포레이티드 염-민감성 유액 시스템을 사용한 사람 눈물막으로의 효율적인 지질 전달 방법
CA2863500A1 (en) * 2012-01-20 2013-07-25 Aratana Therapeutics Nv Eye drop composition
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
UA117768C2 (uk) 2013-12-24 2018-09-25 Сентісс Фарма Прайвет Лімітед Офтальмологічний розчин тартрату бримонідину для місцевого застосування
MX2017006474A (es) 2014-11-25 2017-09-12 Allergan Inc Composiciones oftalmicas estabilizadas de omega 3.
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
AU2016233125A1 (en) * 2015-03-19 2017-09-14 Allergan, Inc. Fixed dose combination of bromonidine and timolol
AU2017310520A1 (en) 2016-08-12 2019-03-21 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
EP3548000B1 (en) * 2017-05-11 2021-11-10 Vyluma Inc. Atropine pharmaceutical compositions
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
EP4142689A1 (en) 2020-04-29 2023-03-08 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
JP2021183606A (ja) * 2020-05-20 2021-12-02 千寿製薬株式会社 ブリモニジンを含有する液体製剤

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL286080A (hu) * 1961-11-30
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4145421A (en) * 1977-04-22 1979-03-20 Sandoz Ltd. Treating spastic conditions
US4474787A (en) 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4530920A (en) 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
GB9017353D0 (en) 1990-08-08 1990-09-19 Merck Sharp & Dohme Chemical process
JPH07508716A (ja) 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
AU6124494A (en) 1993-01-28 1994-08-15 University Of Iowa Research Foundation, The Ophthalmic uses of signa agonists
EP0723447B1 (en) 1993-10-13 2002-12-11 Allergan, Inc. Use of (2-imidazolin-2-ylamino) quinoxaline derivatives
US5994110A (en) 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
ZA965837B (en) 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
EP0834308A1 (en) 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
EP0975607A1 (en) 1997-04-18 2000-02-02 Abbott Laboratories A process for the preparation of highly pure 6,7-dichloro-5- nitro-2,3-dihydroquinoxaline-2,3-dione
WO1999043299A2 (en) 1998-02-26 1999-09-02 Abbott Laboratories Oral formulation for hydrophilic drugs
AU740586B2 (en) 1998-04-07 2001-11-08 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
WO2000019981A1 (en) * 1998-10-08 2000-04-13 Karagoezian Hampar L Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide
US6514504B1 (en) * 1999-08-18 2003-02-04 The Procter & Gamble Company Discontinuous films from skin care compositions
MXPA02008930A (es) * 2000-07-14 2003-03-31 Allergan Inc Composiciones que contienen componentes agonistas alfa-2-adrenergicos.
DK2153819T3 (da) * 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat

Also Published As

Publication number Publication date
CY1113391T1 (el) 2016-06-22
NZ522610A (en) 2004-11-26
TWI287992B (en) 2007-10-11
NO331816B1 (no) 2012-04-10
HUP0301405A3 (en) 2006-02-28
AU2001273268B2 (en) 2005-08-25
WO2002005822A2 (en) 2002-01-24
JP2004503593A (ja) 2004-02-05
KR20030023700A (ko) 2003-03-19
US20020071874A1 (en) 2002-06-13
WO2002005822A3 (en) 2002-05-02
RU2291685C2 (ru) 2007-01-20
CN1441679A (zh) 2003-09-10
ZA200209877B (en) 2003-09-29
EP1301210A2 (en) 2003-04-16
EP2153819B1 (en) 2012-09-05
ES2392636T3 (es) 2012-12-12
US20030153530A1 (en) 2003-08-14
HU230383B1 (hu) 2016-03-29
IL153322A0 (en) 2003-07-06
CA2416169A1 (en) 2002-01-24
US6562873B2 (en) 2003-05-13
BR0112461A (pt) 2003-07-22
MXPA02012206A (es) 2003-06-04
EP2153819A3 (en) 2010-05-12
IL153322A (en) 2011-01-31
DK2153819T3 (da) 2012-12-03
NO20030153L (no) 2003-01-13
NO20030153D0 (no) 2003-01-13
PT2153819E (pt) 2012-11-14
AR035039A1 (es) 2004-04-14
EP2153819A2 (en) 2010-02-17
CA2416169C (en) 2008-09-23
AU7326801A (en) 2002-01-30
PL361027A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
HUP0303197A2 (hu) Alfa-2-adrenerg agonista komponenseket tartalmazó készítmények
MY143795A (en) Tetrahydropyridoindole derivatives
IL153297A0 (en) Compounds and compositions for delivering active agents
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
HK1036969A1 (en) Compounds and compositions for delivering active agents
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
EA200600750A1 (ru) Трансдермальная фармацевтическая композиция
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
SE0203817D0 (sv) New composition
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa